Improving accountability in vaccine decision-making

References

• Frenk J, Moon S. Governance challenges in global health. N Engl J Med. 2013;368:936–942.
   PubMed Web of Science ®Google Scholar
• Koff WC, Burton DR, Johnson PR, et al. Accelerating next-generation vaccine development for global disease prevention. Science. 2013;340(6136):1232910. DOI:10.1126/science.1232910
   PubMed Web of Science ®Google Scholar
• Black S. The role of health economic analyses in vaccine decision making. Vaccine. 2013;31:6046–6049.
   PubMed Web of Science ®Google Scholar
• OECD. Fiscal sustainability of health systems. Paris: OECD Publishing; 2015. DOI:10.1787/9789264233386-en
   Google Scholar
• Nicod E. Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries. Eur J Health Econ. 2016;18:715–730.
   Web of Science ®Google Scholar
• Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the economic evaluation of health care programmes. 4th ed. Oxford: Oxford University Press; 2015.
   Google Scholar
• Ultsch B, Damm O, Beutels P, et al. Methods for health economic evaluation of vaccines and immunization decision frameworks: a Consensus framework from a European vaccine economics community. Pharmacoeconomics. 2016;34:227–244.
   PubMed Web of Science ®Google Scholar
• Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics. 2008;26:191–215.
   PubMed Web of Science ®Google Scholar
• Jit M, Newall AT, Beutels P. Key issues for estimating the impact and cost-effectiveness of seasonal influenza vaccination strategies. Hum Vaccin Immunother. 2013;9:834–840.
   PubMed Web of Science ®Google Scholar
• Marsh K, Phillips CJ, Fordham R, et al. Estimating cost-effectiveness in public health: a summary of modelling and valuation methods. Health Econ Rev. 2012;2:17.
   PubMedGoogle Scholar
• Black S. Potential long term vaccine benefits poorly translate in cost effectiveness modelling. BMJ. 2014;349:g6764.
   PubMed Web of Science ®Google Scholar
• Phelps C. Antibiotic resistance, mutation. Timmis JK, editor. 2015.
   Google Scholar
• Black S. Generalisability of trial data to the real world. In: Timmis JK, editor. 2015.
   Google Scholar
• James C, Carrin G, Savedoff W, et al. Clarifying efficiency-equity tradeoffs through explicit criteria, with a focus on developing countries. Health Care Anal. 2005;13:33–51.
   PubMed Web of Science ®Google Scholar
• Mina MJ, Metcalf CJE, de Swart RL, et al. Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality. Science. 2015;348:694–699.
   PubMed Web of Science ®Google Scholar
• Beutels P, Edmunds WJ, Antonanzas F, et al. Viral hepatitis prevention B. Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. Pharmacoeconomics. 2002;20:1–7.
   PubMed Web of Science ®Google Scholar
• O’Mahony JF, Paulden M. NICE’s selective application of differential discounting: ambiguous, inconsistent, and unjustified. Value Health. 2014;17:493–496.
   PubMed Web of Science ®Google Scholar
• Barnighausen T, Bloom DE, Cafiero-Fonseca ET, et al. Valuing vaccination. Proc Natl Acad Sci USA. 2014;111:12313–12319.
   PubMed Web of Science ®Google Scholar
• Landefeld JS, Seskin EP. The economic value of life: linking theory to practice. Am J Public Health. 1982;72:555–566.
   PubMed Web of Science ®Google Scholar
• Dore MHI, Singh RG. Economic valuation of life. In: Bobrowsky P, editor. Encyclopedia of natural Hazards. Encyclopedia of earth sciences series. Netherlands: Springer; 2013. p. 240–242.
   Google Scholar
• Chen SY, Anderson S, Kutty PK, et al. Health care–associated measles outbreak in the United States after an importation: challenges and economic impact. J Infect Dis. 2011;203:1517–1525.
   PubMed Web of Science ®Google Scholar
• Ozawa S, Portnoy A, Getaneh H, et al. Modeling the economic burden of adult vaccine-preventable diseases in the United States. Health Aff. 2016;2124–2132.
   Web of Science ®Google Scholar
• Siddiqui M, Salmon DA, Omer SB. Epidemiology of vaccine hesitancy in the United States. Hum Vaccin Immunother. 2013;9:2643–2648.
   PubMed Web of Science ®Google Scholar
• Larson HJ, Jarrett C, Schulz WS, et al. Measuring vaccine hesitancy: the development of a survey tool. Vaccine. 2015;33:4165–4175.
   PubMed Web of Science ®Google Scholar
• MacDonald NE. Vaccine hesitancy: definition, scope and determinants. Vaccine. 2015;33:4161–4164.
   PubMed Web of Science ®Google Scholar
• Kaaniche A, Troubat A, Sherwood A. Does conditional marketing authorisation influence market access in France, England, and Germany? Value Health. 2015;18:A559.
   PubMed Web of Science ®Google Scholar
• OECD. Health expenditure and financing indicator; France, Germany, Sweden, UK; 2015. 2016 [cited 2016 08]. Available from: http://stats.oecd.org/Index.aspx?DataSetCode=SHA
   Google Scholar
• Nohynek H, Wichmann O, D’Ancona F. National advisory groups and their role in immunization policy-making processes in European countries. Clin Microbiol Infect. 2013;19:1096–1105.
   PubMed Web of Science ®Google Scholar
• Bryson M, Duclos P, Jolly A, et al. A systematic review of national immunization policy making processes. Vaccine. 2010;28(Suppl 1):A6–12.
   PubMed Web of Science ®Google Scholar
• Gessner BD, Duclos P, Deroeck D, et al. Informing decision makers: experience and process of 15 National Immunization Technical Advisory Groups. Vaccine. 2010;28(Suppl 1):A1–5.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global vaccine action plan - monitoring, evaluation & accountability: secretariat annual report 2016. Geneva: WHO Press; 2016.
   Google Scholar
• Takla A, Wichmann O, Carrillo-Santisteve P, et al.; Group VINS. Characteristics and practices of National Immunisation Technical Advisory Groups in Europe and potential for collaboration, April 2014. Euro Surveill. 2015;20(9). pii: 21049.
   PubMedGoogle Scholar
• Ricciardi GW, Toumi M, Weil-Olivier C, et al. Comparison of NITAG policies and working processes in selected developed countries. Vaccine. 2015;33:3–11.
   PubMed Web of Science ®Google Scholar
• European medicines agency’s committee for medicinal products for human use. Bexsero; 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002333/WC500134836.pdf
   Google Scholar
• European medicines agency’s committee for medicinal products for human use. European Medicines Agency recommends approval of first vaccine for meningitis B; 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2012/11/WC500134846.pdf
   Google Scholar
• Public Health England. Invasive meningococcal disease in England 2005/06 – 2014/15 Department of Health (UK Government). 2015. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/457379/Invasive_Meningococcal_Disease_data_slideset__Aug15_.ppt
   Google Scholar
• Joint Committee on Vaccination and Immunisation. JCVI interim position statement on use of Bexsero® meningococcal B vaccine in the UK. London: Department of Health; 2013.
   Google Scholar
• Christensen H, Hickman M, Edmunds WJ, et al. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine. 2013;31:2638–2646.
   PubMed Web of Science ®Google Scholar
• Mekalanos JJ. Vaccine economics: what price human life? Sci Transl Med. 2013;5(204ed16).
   PubMed Web of Science ®Google Scholar
• Moxon R, Snape MD. The price of prevention: what now for immunisation against meningococcus B? The Lancet. 2013;382:369–370.
   PubMed Web of Science ®Google Scholar
• Meningitis Now. Campaign timeline: Meningitis Now. 2017 [cited 2016 Oct 08]. Available from: https://www.meningitisnow.org/how-we-help/campaigns/beat-it-now/campaign-timeline/
   Google Scholar
• Christensen H, Trotter CL, Hickman M, et al. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study. BMJ. 2014;349:g5725.
   Google Scholar
• Joint Committee on Vaccination and Immunisation. JCVI position statement on use of Bexsero® meningococcal B vaccine in the UK. London: Department of Health; 2014.
   Google Scholar
• Beutels P, Jit M. A brief history of economic evaluation for human papillomavirus vaccination policy. Sex Health. 2010;7:352–358.
   PubMed Web of Science ®Google Scholar
• Claxton K, Martin S, Soares M, et al. Methods for the estimation of the National Institute for Health and care excellence cost-effectiveness threshold. Health Technol Assess. 2015;19(1–503):v–vi.
   Google Scholar
• Raftery JP. NICE’s cost-effectiveness range: should it be lowered? Pharmacoeconomics. 2014;32:613–615.
   PubMed Web of Science ®Google Scholar
• Rawlins M, Barnett D, Stevens A. Pharmacoeconomics: NICE’s approach to decision-making. Br J Clin Pharmacol. 2010;70:346–349.
   PubMed Web of Science ®Google Scholar
• Baltussen R. Question is not whether but how to use MCDA. Value & Outcome Spotlight. 2015;1:14–16.
   Google Scholar
• Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8:165–178.
   PubMedGoogle Scholar
• Pedersen K, Burger EA, Sy S, et al. Cost-effective management of women with minor cervical lesions: revisiting the application of HPV DNA testing. Gynecol Oncol. 2016;143:326–333.
   PubMed Web of Science ®Google Scholar
• Bloom DE, Canning D, Shenoy ES. The effect of vaccination on children’s physical and cognitive development in the Philippines. Appl Econ. 2011;44:2777–2783.
   Web of Science ®Google Scholar
• Bärnighausen T, Berkley S, Bhutta ZA, et al. Reassessing the value of vaccines. The Lancet Global Health. 2014;2:e251–e2.
   PubMed Web of Science ®Google Scholar
• Bloom DE. Valuing vaccines: deficiencies and remedies. Vaccine. 2015;33(Suppl 2):B29–33.
   PubMed Web of Science ®Google Scholar
• Psacharopoulos G. Rates of return to investment in education around the world. Comp Educ Rev. 1972;16:54–67.
   Web of Science ®Google Scholar
• Mansbridge J. The fallacy of tightening the reins. Österreichische Zeitschrift Für Politikwissenschaft. 2005;34:233–247.
   Google Scholar
• Keohane RO. Global governance and democratic accountability. In: Held D, Koenig-Archibugi M, editor. Taming globalization: frontiers of governance. Oxford: Polity Press; 2003. p. 130–159.
   Google Scholar
• Timmis JK, Rigat F, Rappuoli R. Core values for vaccine evaluation. Vaccine. 2017;35(Supplement 1):A57–A62.
   PubMed Web of Science ®Google Scholar
• Institute of Medicine. Ranking vaccines: a prioritization framework: phase I: demonstration of concept and a software blueprint. Washington (DC): The National Academies Press; 2012.
   Google Scholar
• Seok B. Collective decision problem. In: Chatterjee D, editor. Encyclopedia of global justice. Netherlands: Springer; 2011. p. 155–156.
   Google Scholar
• Marsh K, Ijzerman M, Thokala P, et al. Multiple criteria decision analysis for health care decision making—emerging good practices: report 2 of the ISPOR MCDA emerging good practices task force. Value Health. 2016;19:125–137.
   PubMed Web of Science ®Google Scholar
• Thokala P, Devlin N, Marsh K, et al. Multiple criteria decision analysis for health care decision making–an introduction: report 1 of the ISPOR MCDA emerging good practices task force. Value Health. 2016;19:1–13.
   PubMed Web of Science ®Google Scholar
• Devlin N, Sussex J. Incorporating multiple criteria in HTA: methods and processes. London: Office of Health Economics; 2011.
   Google Scholar
• Claxton K. Three questions to ask when examining MCDA. Value & Outcome Spotlight. 2015;1:18–20.
   Google Scholar
• Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96:5–21.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Health-Related Quality of Life (HRQOL) 2016 [cited 2016 Oct 20]. Available from: https://www.cdc.gov/hrqol/
   Google Scholar
• The National Academies Press. SMART vaccines: strategic multi-attribute ranking tool for vaccines. Washington (DC): National Academy of Sciences; 2016 [cited 2016 Dec 09]. Available from: http://www.nap.edu/smartvaccines/
   Google Scholar
• Barron FH, Barrett BE. The efficacy of SMARTER—simple multi-attribute rating technique extended to ranking. Acta Psychologica. 1996;1:23–36.
   Web of Science ®Google Scholar
• Peters A. The transparency of global governance. In: Pazartzis P, Gavouneli M, editors. Reconceptualising the Rule of Law in Global Governance, Resources, Investment and Trade. 1st ed. Oxford and Portland: Hart Publishing; 2016, p. 3–10.
   Google Scholar
• Bærøe K, Baltussen R. Legitimate healthcare limit setting in a real-world setting: integrating accountability for reasonableness and multi-criteria decision analysis. Public Health Ethics. 2014;7:98–111.
   Web of Science ®Google Scholar
• Reh C. Is informal politics undemocratic? Trilogues, early agreements and the selection model of representation. J Eur Public Policy. 2014;21:822–841.
   Web of Science ®Google Scholar
• de Fine Licht J, Naurin D, Esaiasson P, et al. When acy? Experidoes transparency generate legitimmenting on a context-bound relationship. Governance. 2014;27:111–134.
   Web of Science ®Google Scholar
• Mansbridge J. Clarifying the concept of representation. Am Political Sci Rev. 2011;105:621–630.
   Web of Science ®Google Scholar
• Martin DK, Giacomini M, Singer PA. Fairness, accountability for reasonableness, and the views of priority setting decision-makers. Health Policy. 2002;61:279–290.
   PubMed Web of Science ®Google Scholar
• de Fine Licht J. Magic Wand or Pandora’s Box: how transparency in decision making affects public perceptions of legitimacy - Dissertation. Gothenburg; 2014.
   Google Scholar
• Daniels N, Sabin JE. Setting Limits Fairly: can we learn to share medical resources? New York: Oxford University Press; 2002.
   Google Scholar
• Madhavan G. SMART Vaccines – current state of affairs. In: Timmis JK, editor. Attributes chosen by SMART Vaccines users not recorded in the present versionWeb-based version planned by HHS ed. 2015.
   Google Scholar
• Gorin M, Joffe S, Dickert N, et al. Justifying clinical nudges. Hastings Cent Rep. 2017;47:32–38.
   PubMed Web of Science ®Google Scholar
• Bryant J, Sanson-Fisher R, Walsh J, et al. Health research priority setting in selected high income countries: a narrative review of methods used and recommendations for future practice. Cost Eff Resour Alloc. 2014;12:23.
   PubMed Web of Science ®Google Scholar
• Tromp N, Baltussen R. Mapping of multiple criteria for priority setting of health interventions: an aid for decision makers. BMC Health Serv Res. 2012;12:454.
   Web of Science ®Google Scholar
• Norheim O, Baltussen R, Johri M, et al. Guidance on priority setting in health care (GPS-Health): the inclusion of equity criteria not captured by cost-effectiveness analysis. Cost Eff Resour Alloc. 2014;12:18.
   PubMed Web of Science ®Google Scholar
• Timmis JK Healthcare Systems and Health Technology Assessment A comparative clusters analysis [Thesis]. Freiburg: not published; 2016.
   Google Scholar